Bethan Hopewell is “very sensible to deal with” according to impressed sources who commend her deep expertise in patent licensing and litigation proceedings.
Bethan is a partner of Powell Gilbert LLP (www.powellgilbert.com), a specialist intellectual property law firm.
Bethan has a degree in biology from Imperial College and a DPhil in molecular biology from the University of Oxford. She advises on a range of contentious IP matters, with a strong focus on multi-jurisdictional patent disputes. She works on matters concerning a variety of technologies, but is particularly known for her expertise in advising clients on complex patent matters, pharmaceutical regulatory issues and contested supplementary protection certificate disputes in the life sciences sector.
Bethan represents clients in litigation before the UK Patents Court, Court of Appeal and Supreme Court. She also represents clients in the European Patent Office at opposition and appeal proceedings, and advises on referrals to the CJEU on questions relating to SPC regulations.
UK cases in which Bethan has been involved include Dr Reddy’s v Eli Lilly (olanzapine), Sandoz/ratiopharm v Napp (controlled release oxycodone), Eli Lilly v Human Genome Sciences (Neutrokine-alpha and SPCs), Actavis v Warner-Lambert and Warner-Lambert v Actavis (pregabalin); Merck Sharp & Dohme Corp v Royalty Pharma Collection Trust (DPP-IV inhibitors), Illumina & ors v Premaitha/ TDL Genetics Ltd & ors (non-invasive prenatal testing), Chugai v UCB (patent licence dispute).
Bethan frequently speaks on IP law issues and is a tutor on the Oxford University diploma in intellectual property law and practice course. Bethan is a member of AIPPI, LSLA and CIPA.